Science 37 was the top enrolling site, contributing 47% of total U.S. study participants. Despite joining the trial 6 months later, enrollment was 11x faster compared to the other 141 participating traditional brick-and-mortar sites. Science 37 also achieved an 82% retention rate in patients transferred from traditional sites who were at risk of dropping out.

Science 37 was the top enrolling site, enrolling 55% of total study participants and achieving a 98% visit completion rate. While each of the participating traditional brick-and-mortar sites averaged less than 1 patient enrolled, Science 37 enrolled 33 patients. Science 37 also contributed 77% of the required completers for interim analysis.

Science 37 was the top enrolling site, contributing 28% of total enrolled patients over a 15-month window. Science 37 enrolled 44 patients per month, demonstrating an enrollment velocity 22x greater than traditional brick-and-mortar sites (averaging only 2 patients per month), and reducing the study’s overall time-to-target enrollment.

Science 37 was the top enrolling site, contributing 25% of all randomized patients nationwide. Through its Direct-to-Patient Site, which proved well-suited for this hard-to-enroll, rare disease population, including pediatric patients, Science 37 achieved a 94% patient retention rate.

Science 37 was the top enrolling site, contributing 42% of total participants across 36 states in just 8 weeks for the study's immunocompromised cohort. Science 37 achieved a >90% visit completion rate across over 700 in-home visits, and notably, included 23% minority representation.

Science 37 was the top enrolling site globally in a multinational clinical trial spanning North America, Europe, Latin America, and Asia-Pacific. Brought in to revitalize recruitment efforts and boost patient randomization, Science 37 played a pivotal role in re-engaging the rare PSC community, raising awareness, and helping to put the study timeline back on track.

Science 37 was the top enrolling site, delivering 42% of total study enrollment and outperforming the other 100 traditional sites. Enrolling patients across 49 states, Science 37 achieved 24% minority representation and exceeded its contracted goal with over 12,000 participants (original goal: 7,000), accelerating the study timeline by over 3 years.

Science 37 supported a Phase 3 atrial fibrillation trial, overcoming strict protocol criteria, an older target demographic, and initial enrollment delays through targeted process improvements and close sponsor collaboration.

Science 37 enrolled all study participants across 19 U.S. states as a single Direct-to-Patient Site, successfully managing a difficult-to-enroll population with a rare genetic disorder, limited eligible patients, broad geographic dispersion, and a complex, closely monitored, long-duration (40 months with OLE) protocol.

As the top enrolling site among 52 research locations, Science 37 enrolled 21% of all study participants—11x faster than traditional brick-and-mortar sites. The sponsor expanded Science 37’s contracted capacity after the team exceeded initial enrollment projections.